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OpThe problem of the most appropriate curative treatment for
hepatocellular carcinoma. When to embolize? When to operate?malignancies, the best chance for a cure is surgical extirpation
[2,5]. It has already been demonstrated that the recommendation
whether to receive surgery is largely inﬂuenced by the type of
specialist by whom patients are seen initially [6].
In this regard, what several authors lately observed [6,7] shar-
ply indicates the need for further evidence on treatment strate-
gies and stronger collaboration among specialists, especially
considering how much has changed through the last decades in
the rapidly maturing ﬁeld of hepatic surgery.
First, liver resection indications for HCC have been imple-
mented with new surgical treatments: the Associating Liver
Partition and Portal vein ligation for Staged hepatectomy
(ALPPS) procedure may increase the rate of curative resections
for tumours previously considered unresectable for major vascu-
lar invasion or tumour thrombosis [8].
Second, it must be considered that with the diffusion of mod-
ern technologies, the signiﬁcant rate of morbidity and mortality
historically associated with hepatic surgery has decreased dra-
matically. Advanced laparoscopy as well as robotics now permit
oncologically adequate and safe surgery with the advantages of
the minimally invasive method and respected principles of par-
enchyma-sparing surgery [9,10].
Given the signiﬁcant rise in prevalence of predisposing condi-
tions, in coming years hepatologists will be increasingly con-
fronted with the question of the most appropriate therapy for
HCC patients. Currently, a substantive mismatch exists between
the possibility of receiving curative surgery and its application
[7].
While we agree with the successful nonoperative manage-
ment of HCC patients with TACE, we further commend that all
patients with potentially resectable HCC should be routinely
evaluated in dedicated centres with large experience of liver sur-
gery, possibly where the technological progress is part of daily
surgical practice. Otherwise, we are possibly missing a valuable
opportunity to signiﬁcantly improve the patients’ survival and
quality of life.
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In the Journal of Hepatology, Kim and colleagues [1] recently pub-
lished an interesting and timely observation on the prognostic
signiﬁcance of treatment responses following transarterial
chemoembolization (TACE) for patients with hepatocellular carci-
noma (HCC).
We congratulate the authors for their paper, which was read
with great interest because of the special need of published,
speciﬁc analyses on this matter. Actually, the implications of their
ﬁndings can be of signiﬁcant value in clinical practice, especially
considering potential predictive applications. However, with
regard to methodology, some aspects require further considera-
tion as we are concerned that the selection criteria used may
impair the power of the analysis and the possibility to draw
deﬁnitive conclusions from their outcomes.
As exclusion criteria the authors considered ﬁve thorough fea-
tures: inadequate target lesion (inﬁltrative pattern or largest
lesion being smaller than one centimetre), other primary or sec-
ondary malignancies, presence of extrahepatic tumour lesions
and/or invasion to main portal vein, Child-Pugh class different
from A and presence of uncontrolled functional or metabolic dis-
ease. Some perplexities arise.
The clinical and radiological conditions evaluated by the
inclusion protocol are likely to admit a number of patients which
may represent optimal candidates to surgical resection. In this
regard, it would be extremely interesting to know how many
included patients had very early (0), early (A) and intermediate
(B) stage according to the Barcelona Clinic Liver Cancer (BCLC)
classiﬁcation at preprocedural assessment. Likewise, it would
be interesting to know on the basis of which criteria unresectabil-
ity was assessed, by considering that the median tumour size was
reported to be 3.1 centimetres, with the number of lesions being
<4 for the largest majority of cases. Of note, large and multiple
tumours were ﬁnally independently associated with failure to
achieve complete response after the initial TACE treatment.
Thus, better responses were observed in patients with small, sin-
gle or few intrahepatic lesions, preserved liver function and,
potentially, low co-morbidity. In fact, the outcomes should be
more appropriately analysed in comparison with those of surgical
resection given that the subgroup of patients who experienced
better results was likely to include a number of excellent candi-
dates to liver resection.
In this regard, in a recent, extremely interesting multicentric
study published by Vitale et al. [2], including more than 2000
patients with HCC and preserved liver function, resection was
conﬁrmed to be associated with signiﬁcant survival beneﬁt over
loco-regional therapies, regardless of BCLC stages. Furthermore,
it has been demonstrated that radical therapies such as surgical
resection and liver transplantation achieve better results and
are increasingly employed even in HCC patients with intermedi-
ate and advanced diseases [3,4].
The problem of offering HCC patients the most appropriate
therapy is not new. Indeed, although it is largely known that in
patients with preserved hepatic function and resectable0 Journal of Hepatology 2015 vol. 63 j 276–288
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Reply to ‘‘The problem of the most appropriate curative treatment for
hepatocellular carcinoma. When to embolize? When to operate?’’
To the Editor:
We appreciate the valuable comments by Guerra et al. on our
recently published article [1]. They raised some issues.
We recognize that surgical resection should be considered
ﬁrst, provided that patients are clinically eligible for this
approach when considering liver function, portal pressure, rem-
nant liver volume after surgical resection, and performance sta-
tus. Vitale et al. [2] indicated that surgical resection can prolong
survival compared with loco-regional therapy in patients with
hepatocellular carcinoma (HCC), regardless of the Barcelona
Clinic Liver Cancer (BCLC) stage, provided that liver dysfunction
(Child-Pugh Class B or Model for End-stage Liver Disease score
>9) and poor performance status (Eastern Cooperative Oncology
Group >1) are absent. Indeed, it is more important to identify
optimal candidates who will beneﬁt from multi-disciplinary
approaches rather than offering a formulaic treatment modality.
Accordingly, nonsurgical approaches can also be considered in a
patient with early stage HCC to avoid the risk of postoperative
complications, including hepatic insufﬁciency and mortality, par-
ticularly for those with a morphologically cirrhotic liver on a pre-
operative radiological assessment. In this clinical setting,
orthotopic liver transplantation (OLT) is a better option than sur-
gical resection as it manages the underlying cirrhotic liver and
HCC simultaneously. However, OLT is often ineligible due to the
shortage of appropriate donors in South Korea.
Approximately, one-third of our study participants had a
tumor burden within the Milan criteria [3], i.e., BCLC early stage,
in which surgical resection or OLT may be recommended accord-
ing to the degree of underlying liver disease. Surgical resection
should be performed with caution in highly selected patients
with BCLC early stage HCC and a morphologically cirrhotic liver,
if they do not receive a suitable graft quickly. Furthermore,
although patients who show BCLC early stage HCC and morpho-
logically non-cirrhotic liver may be obviously good candidates for
surgical resection, nonsurgical approaches can be considered in
clinical practices for several reasons, such as patient refusal to
undergo surgical resection, old age, relatively poor performance
status, accompanying co-morbidities, evidence of portal hyper-
tension, high indocyanine green retention test at 15 min, high
liver stiffness value assessed using transient elastography [4,5],
and inappropriate location for surgical resection based on the
remnant liver volume.
The major aim of our study was to assess the impact of achiev-
ing a complete response (CR) at an early time point among
patients with HCC treated with transarterial chemoembolization
(TACE), not to compare the clinical outcomes between treatment
modalities. When we stratiﬁed the 298 patients without tumor
invasion of the peripheral portal vein branches into three groups;
patients within the Milan criteria [3], patients beyond the Milan
criteria, but within the up-to-seven criteria [6], and patients
beyond the up-to-seven criteria, the patients within the Milan
criteria had the highest CR rate (initial response, 82.9%), followed
by those beyond the Milan criteria, but within the up-to-seven
criteria (59.2%) (p <0.001 vs. those within the Milan criteria),
and those beyond the up-to-seven criteria (13.7%) (p <0.001 vs.
those beyond the Milan criteria, but within the up-to-seven crite-
ria). Similarly, in the view of achieving a CR as the best response,
patients within the Milan Criteria had the highest CR rate of
88.6%, followed by those beyond the Milan criteria, but within
the up-to-seven criteria with 74.5% (p = 0.009 vs. those within
the Milan criteria) and those beyond the up-to-seven criteria
with 40.0% (p <0.001 vs. those beyond the Milan, but within the
up-to-seven criteria) (Table 1). We agree that better clinical out-
comes are anticipated after TACE in patients with a smaller tumor
burden, but the prognostic signiﬁcance of achieving a CR as the
initial and best response was also observed in all three sub-
groups. Patients who achieved a CR (both initial and best
response) had a longer median overall survival than the others
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